Halia Therapeutics, Inc. — Form D
Halia Therapeutics, Inc. of Lehi, UT, a company, filed a Form D exempt-offering notice with the SEC on 2022-12-30. The offering totals $50.0M, of which $12.2M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2022-12-30
- Form: D
- Accession: 0001829255-22-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $50.0M
- Amount sold: $12.2M
- Remaining: $37.8M
- Investors: 24
- Date of first sale: 2022-12-16
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-469248
Issuer
- Name: Halia Therapeutics, Inc.
- CIK: 0001829255
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2017
- Address: 3900 N. Traverse Mountain Blvd, Lehi, UT, 84043
- Phone: 385-355-4315
Officers, directors & promoters (15)
| Name | Role | Location |
|---|
| Jim SK Savas | Director | Salt Lake City, UT |
| Jim B Savas | Director | Lehi, UT |
| David Bearss | Director | Salt Lake City, UT |
| David Bearss | Executive Officer | Salt Lake City, UT |
| David Bearss | Promoter | Salt Lake City, UT |
| Jeffrey Burton | Executive Officer | Lehi, UT |
| Todd SK Pedersen | Director | Lehi, UT |
| Jared Bearss | Director | Lehi, UT |
| Jared Bearss | Executive Officer | Lehi, UT |
| Jared Bearss | Promoter | Lehi, UT |
| John SK Kauwe | Director | Lehi, UT |
| John SK Kauwe | Promoter | Lehi, UT |
| MIKE SK MCCULLAR | Director | SALT LAKE CITY, UT |
| MIKE SK MCCULLAR | Executive Officer | SALT LAKE CITY, UT |
| Gary B Sabin | Director | San Diego, CA |
Other filings by this issuer (3)
More